Antiatherothrombotic effects of nicotinic acid

被引:61
作者
Rosenson, RS [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Prevent Cardiol Ctr, Chicago, IL 60612 USA
关键词
atherosclerosis; thrombosis fibrinolysis; viscosity; lipids; coronary heart disease risk; niacin;
D O I
10.1016/j.atherosclerosis.2003.07.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular event reduction in hypercholesterolemic subjects appropriately emphasizes the prominent role of statin therapy; however, niacin (nicotinic acid) is also an effective lipid-altering agent that prevents atherosclerosis and reduces cardiovascular events. Niacin has multifarious lipoprotein and anti-atherothrombosis effects that improve endothelial function, reduce inflammation, increase plaque stability, and diminish thrombosis. Niacin reduces the atherogenicity of low-density lipoprotein (LDL) by changing the distribution of small LDL to large LDL subclass, and the susceptibility of LDL to oxidative modification. It is the most effective agent for increasing high-density lipoprotein cholesterol. Moreover, it favorably alters high-density lipoprotein composition, increasing apolipoprotein AI relative to apolipoprotein All. Niacin reduces blood viscosity through a variety of mechanisms, thus improving blood flow and per-fusion through stenotic segments of the vasculature. Finally, niacin has cardioprotective effects that may limit ischemia-reperfusion injury. By preserving glycolysis during periods of ischemia and improving subendocardial blood flow during reperfusion, niacin can improve the functional recovery of the myocardium. (C) 2003 Elsevier Ireland Ltd. All fights reserved.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 91 条
[1]   Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl [J].
Andrews, TC ;
Whitney, EJ ;
Green, G ;
Kalenian, R ;
Personius, BE .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (07) :831-835
[2]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[3]   PROSTAGLANDIN-I2 HALF-LIFE REGULATED BY HIGH-DENSITY-LIPOPROTEIN IS DECREASED IN ACUTE MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA-PECTORIS [J].
AOYAMA, T ;
YUI, Y ;
MORISHITA, H ;
KAWAI, C .
CIRCULATION, 1990, 81 (06) :1784-1791
[4]   SUBPOPULATIONS OF APOLIPOPROTEIN-A-I IN HUMAN HIGH-DENSITY LIPOPROTEINS THEIR METABOLIC PROPERTIES AND RESPONSE TO DRUG-THERAPY [J].
ATMEH, RF ;
SHEPHERD, J ;
PACKARD, CJ .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 751 (02) :175-188
[5]  
Austin MA, 1999, AM J CARDIOL, V83, p13F
[6]  
AVIRAM M, 1983, HAEMOSTASIS, V13, P344
[7]  
Berg K, 1997, CLIN GENET, V52, P254
[8]   BENEFICIAL-EFFECTS OF COLESTIPOL-NIACIN THERAPY ON THE COMMON CAROTID-ARTERY - 2-YEAR AND 4-YEAR REDUCTION OF INTIMA-MEDIA THICKNESS MEASURED BY ULTRASOUND [J].
BLANKENHORN, DH ;
SELZER, RH ;
CRAWFORD, DW ;
BARTH, JD ;
LIU, CR ;
LIU, CH ;
MACK, WJ ;
ALAUPOVIC, P .
CIRCULATION, 1993, 88 (01) :20-28
[9]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[10]   EFFECTS OF COLESTIPOL-NIACIN THERAPY ON HUMAN FEMORAL ATHEROSCLEROSIS [J].
BLANKENHORN, DH ;
AZEN, SP ;
CRAWFORD, DW ;
NESSIM, SA ;
SANMARCO, ME ;
SELZER, RH ;
SHIRCORE, AM ;
WICKHAM, EC .
CIRCULATION, 1991, 83 (02) :438-447